

Referral Status:	MRN:
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change
<input type="checkbox"/> Order Renewal	
Patient preferred clinic:	

# Tysabri® (natalizumab) Standard Plan of Treatment

## PATIENT DEMOGRAPHICS:

Date of Referral:	Patient's Phone:
Patient Name:	Address:
Date of Birth:	City, State, Zip:
Height in inches:	Weight: LB or KG
Gender:	Allergies:
<input type="checkbox"/> See list	<input type="checkbox"/> NKDA

## DIAGNOSIS: (PLEASE COMPLETE 2<sup>ND</sup> AND 3<sup>RD</sup> DIGITS TO COMPLETE ICD 10 FOR BILLING)

G35 - Relapsing Multiple Sclerosis	K50.9 - Crohn's Disease
K50.8 - Crohn's Disease (small & large intestine)	K50.0 - Crohn's Disease (small intestine)
K50.1 - Crohn's Disease (large intestine)	- Other:

## REQUESTED DOCUMENTATION: PREVIOUS ADMINISTRATION: HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE?

1 Insurance information	IF NO:	IF YES:
2 Most recent History & Physical	PLEASE STATE	LAST INFUSION DATE:
3 Full medication list	REQUIRED WASHOUT	NEXT INFUSION DATE:
4 Tried and failed therapies	FROM PREVIOUS	<b>IF ORDER CHANGE:</b>
5 Anti-JCV antibodies as required by payer or REMS program	THERAPY:	
<b>Continue current order until insurance approved</b>		

## MEDICATION ORDERS:

NOTE: Patient may be ineligible to receive natalizumab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new-onset or deterioration neurological changes, and/or surgery

### PREMEDICATION TO BE ADMINISTERED 30 MINUTES PRIOR TO ADMINISTRATION AS SELECTED

\*FDA labeling suggests that patients who have stopped treatment for an extended period are at higher risk for hypersensitivity reactions. MD should evaluate premedication and consider antibody testing prior to restart of therapy.

<b>IV</b>	Diphenhydramine	25mg	50mg		<b>PO</b>	Acetaminophen	325mg	500mg	650mg	1000mg
	Methylprednisolone	40mg	125mg	Other:		Famotidine	20mg	40mg		
	Famotidine	20mg	40mg			Diphenhydramine	25mg	50mg		
	Other:					Fexofenadine	60mg	180mg		
						Cetirizine	10mg			
				Loratadine	10mg					
				Other:						

## MEDICATION:

Tysabri® (natalizumab) 300 mg in 100 ml NS IV to infuse over at least 1- hour.

Follow first 12 infusions with a one hour post infusion observation.

**FREQUENCY:**

Dosing every 4 weeks, no less than every 28 days.

Other: \_\_\_\_\_

## LAB ORDERS:

Draw JCV antibody test every 6 months

Draw JCV antibody test every \_\_\_\_\_

## SPECIAL/OTHER LAB ORDERS:

\_\_\_\_\_

\_\_\_\_\_

**Prescriber to monitor patient for symptoms of PML as clinically appropriate.**

\*Prior to each infusion: ensure that the patient has a current Notice of Patient Authorization on file to receive Tysabri® (natalizumab) for their diagnosis and complete/submit Pre-infusion Patient Checklist within 24 hours to Biogen Idec

Refills x 12 months unless noted otherwise here:


## CARE ORDERS: ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Start PIV/Access CVC

Flush device per facility standard flushing procedure

Provide nursing care per Palmetto Infusion Nursing Procedures and post procedure observation if indicated

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website or scan here.



## PRESCRIBER INFORMATION:

PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:

## PRESCRIBER SIGNATURE: (No stamp signatures) DATE:

Dispense as written/Brand medically necessary	Substitution permitted



## Checklist for referrals to Palmetto Infusion: Fax referral to 1.800.521.9640

- Patient demographics - address, phone number, SS#, etc.**
- Insurance information - copy of the card(s) if possible**
- Plan of Treatment/Orders**
- Most recent physician office notes to include tried and failed therapies - all insurance companies that require a pre-authorization require the note. This includes Medicare/Medicaid HMOs.**
- Any lab results or other diagnostic procedures to support the diagnosis.**

Palmetto Infusion will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility.

Our office will notify you if any further information is required.

We will review financial responsibility with patient and refer them to any available co-pay assistance as required. Palmetto Infusion Call Center 800.809.1265. Thank you for your referral.

[www.PalmettoInfusion.com](http://www.PalmettoInfusion.com)